Search

Your search keyword '"Benucci,Maurizio"' showing total 14 results
Start Over Author "Benucci,Maurizio" Publisher mdpi ag
14 results on '"Benucci,Maurizio"'

2. Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine

Author

Picchianti-Diamanti, Andrea, primary, Navarra, Assunta, additional, Aiello, Alessandra, additional, Laganà, Bruno, additional, Cuzzi, Gilda, additional, Salmi, Andrea, additional, Vanini, Valentina, additional, Maggi, Fabrizio, additional, Meschi, Silvia, additional, Matusali, Giulia, additional, Notari, Stefania, additional, Agrati, Chiara, additional, Salemi, Simonetta, additional, Di Rosa, Roberta, additional, Passarini, Damiano, additional, Di Gioia, Valeria, additional, Sesti, Giorgio, additional, Conti, Fabrizio, additional, Spinelli, Francesca Romana, additional, Corpolongo, Angela, additional, Chimenti, Maria Sole, additional, Ferraioli, Mario, additional, Sebastiani, Gian Domenico, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Santoro, Anna Paola, additional, Capri, Andrea, additional, Puro, Vincenzo, additional, Nicastri, Emanuele, additional, and Goletti, Delia, additional

Published
2023
Full Text
View/download PDF

3. ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

Author

Benucci, Maurizio, primary, Bardelli, Marco, additional, Cazzato, Massimiliano, additional, Laurino, Elenia, additional, Bartoli, Francesca, additional, Damiani, Arianna, additional, Li Gobbi, Francesca, additional, Panaccione, Anna, additional, Di Cato, Luca, additional, Niccoli, Laura, additional, Frediani, Bruno, additional, Mosca, Marta, additional, Guiducci, Serena, additional, and Cantini, Fabrizio, additional

Published
2023
Full Text
View/download PDF

4. Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases

Author

Manfredi, Mariangela, primary, Van Hoovels, Lieve, additional, Benucci, Maurizio, additional, De Luca, Riccardo, additional, Coccia, Carmela, additional, Bernardini, Pamela, additional, Russo, Edda, additional, Amedei, Amedeo, additional, Guiducci, Serena, additional, Grossi, Valentina, additional, Bossuyt, Xavier, additional, Perricone, Carlo, additional, and Infantino, Maria, additional

Published
2023
Full Text
View/download PDF

5. The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis

Author

Picchianti Diamanti, Andrea, primary, Navarra, Assunta, additional, Cuzzi, Gilda, additional, Aiello, Alessandra, additional, Salemi, Simonetta, additional, Di Rosa, Roberta, additional, De Lorenzo, Chiara, additional, Vio, Daniele, additional, Sebastiani, Giandomenico, additional, Ferraioli, Mario, additional, Benucci, Maurizio, additional, Li Gobbi, Francesca, additional, Cantini, Fabrizio, additional, Polidori, Vittoria, additional, Simmaco, Maurizio, additional, Cialdi, Esmeralda, additional, Scolieri, Palma, additional, Bruzzese, Vincenzo, additional, Nicastri, Emanuele, additional, D’Amelio, Raffaele, additional, Laganà, Bruno, additional, and Goletti, Delia, additional

Published
2023
Full Text
View/download PDF

6. Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. J. Pers. Med. 2022, 12, 1174

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Bandinelli, Francesca, additional, Russo, Edda, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Infantino, Maria, additional, and Manfredi, Mariangela, additional

Published
2023
Full Text
View/download PDF

7. The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Russo, Edda, additional, Guiducci, Serena, additional, Li Gobbi, Francesca, additional, Fusi, Paola, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Manfredi, Mariangela, additional, and Infantino, Maria, additional

Published
2022
Full Text
View/download PDF

8. Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine

Author

Infantino, Maria, primary, Tsalouchos, Aris, additional, Russo, Edda, additional, Laudicina, Selene, additional, Grossi, Valentina, additional, Lari, Barbara, additional, Benucci, Maurizio, additional, Stacchini, Lorenzo, additional, Amedei, Amedeo, additional, Casprini, Patrizia, additional, Villalta, Danilo, additional, Dattolo, Pietro Claudio, additional, and Manfredi, Mariangela, additional

Published
2022
Full Text
View/download PDF

9. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease

Author

Benucci, Maurizio, primary, Damiani, Arianna, additional, Bandinelli, Francesca, additional, Russo, Edda, additional, Li Gobbi, Francesca, additional, Grossi, Valentina, additional, Amedei, Amedeo, additional, Infantino, Maria, additional, and Manfredi, Mariangela, additional

Published
2022
Full Text
View/download PDF

10. Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study

Author

Treppo, Elena, primary, Infantino, Maria, additional, Benucci, Maurizio, additional, Ravagnani, Viviana, additional, Palterer, Boaz, additional, Fabris, Martina, additional, Tomietto, Paola, additional, Manfredi, Mariangela, additional, Giudizi, Maria Grazia, additional, Ligobbi, Francesca, additional, Cammelli, Daniele, additional, Grandis, Marina, additional, Parronchi, Paola, additional, De Vita, Salvatore, additional, and Quartuccio, Luca, additional

Published
2020
Full Text
View/download PDF

11. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

Author

Cavagna, Lorenzo, primary, Trallero-Araguás, Ernesto, additional, Meloni, Federica, additional, Cavazzana, Ilaria, additional, Rojas-Serrano, Jorge, additional, Feist, Eugen, additional, Zanframundo, Giovanni, additional, Morandi, Valentina, additional, Meyer, Alain, additional, Pereira da Silva, Jose, additional, Matos Costa, Carlo, additional, Molberg, Oyvind, additional, Andersson, Helena, additional, Codullo, Veronica, additional, Mosca, Marta, additional, Barsotti, Simone, additional, Neri, Rossella, additional, Scirè, Carlo, additional, Govoni, Marcello, additional, Furini, Federica, additional, Lopez-Longo, Francisco, additional, Martinez-Barrio, Julia, additional, Schneider, Udo, additional, Lorenz, Hanns-Martin, additional, Doria, Andrea, additional, Ghirardello, Anna, additional, Ortego-Centeno, Norberto, additional, Confalonieri, Marco, additional, Tomietto, Paola, additional, Pipitone, Nicolò, additional, Rodriguez Cambron, Ana, additional, Blázquez Cañamero, María, additional, Voll, Reinhard, additional, Wendel, Sarah, additional, Scarpato, Salvatore, additional, Maurier, Francois, additional, Limonta, Massimiliano, additional, Colombelli, Paolo, additional, Giannini, Margherita, additional, Geny, Bernard, additional, Arrigoni, Eugenio, additional, Bravi, Elena, additional, Migliorini, Paola, additional, Mathieu, Alessandro, additional, Piga, Matteo, additional, Drott, Ulrich, additional, Delbrueck, Christiane, additional, Bauhammer, Jutta, additional, Cagnotto, Giovanni, additional, Vancheri, Carlo, additional, Sambataro, Gianluca, additional, De Langhe, Ellen, additional, Sainaghi, Pier, additional, Monti, Cristina, additional, Gigli Berzolari, Francesca, additional, Romano, Mariaeva, additional, Bonella, Francesco, additional, Specker, Christof, additional, Schwarting, Andreas, additional, Villa Blanco, Ignacio, additional, Selmi, Carlo, additional, Ceribelli, Angela, additional, Nuno, Laura, additional, Mera-Varela, Antonio, additional, Perez Gomez, Nair, additional, Fusaro, Enrico, additional, Parisi, Simone, additional, Sinigaglia, Luigi, additional, Del Papa, Nicoletta, additional, Benucci, Maurizio, additional, Cimmino, Marco, additional, Riccieri, Valeria, additional, Conti, Fabrizio, additional, Sebastiani, Gian, additional, Iuliano, Annamaria, additional, Emmi, Giacomo, additional, Cammelli, Daniele, additional, Sebastiani, Marco, additional, Manfredi, Andreina, additional, Bachiller-Corral, Javier, additional, Sifuentes Giraldo, Walter, additional, Paolazzi, Giuseppe, additional, Saketkoo, Lesley, additional, Giorgi, Roberto, additional, Salaffi, Fausto, additional, Cifrian, Jose, additional, Caporali, Roberto, additional, Locatelli, Francesco, additional, Marchioni, Enrico, additional, Pesci, Alberto, additional, Dei, Giulia, additional, Pozzi, Maria, additional, Claudia, Lomater, additional, Distler, Jorg, additional, Knitza, Johannes, additional, Schett, George, additional, Iannone, Florenzo, additional, Fornaro, Marco, additional, Franceschini, Franco, additional, Quartuccio, Luca, additional, Gerli, Roberto, additional, Bartoloni, Elena, additional, Bellando Randone, Silvia, additional, Zampogna, Giuseppe, additional, Gonzalez Perez, Montserrat, additional, Mejia, Mayra, additional, Vicente, Esther, additional, Triantafyllias, Konstantinos, additional, Lopez-Mejias, Raquel, additional, Matucci-Cerinic, Marco, additional, Selva-O’Callaghan, Albert, additional, Castañeda, Santos, additional, Montecucco, Carlomaurizio, additional, and Gonzalez-Gay, Miguel, additional

Published
2019
Full Text
View/download PDF

12. Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).

Author

Benucci M, Bardelli M, Cazzato M, Bartoli F, Damiani A, Li Gobbi F, Bandinelli F, Panaccione A, Di Cato L, Niccoli L, Frediani B, Mosca M, Guiducci S, and Cantini F

Abstract

Background: According to recent data, the age of patients could represent an important risk factor for MACE (major cardiovascular events), cancer, and VTE (venous thromboembolism) during treatment with JAK inhibitors in rheumatoid arthritis. We decided to analyze the population involved in the ReLiFiRa study by identifying two groups of patients: 65 years or more and less than 65 years of age, evaluating the efficacy and tolerability of 200 mg of Filgotinib daily., Methods: Of the 120 ReLiFiRa patients, 54 were younger than 65 years old and 66 patients were 65 years old or older. The data of efficacy and tolerability of treatment with FIL 200 mg daily for 6 months were evaluated., Results: After six months of treatment, FIL was effective in both age groups. In both groups, the median values of steroid DAS28, CDAI, ERS, PCR, tender joints, swollen joints, VAS, HAQ, PGA patients, and PGA physicians were reduced with a statistically significant difference comparing these values with the baseline values. The difference in age did not impact the effectiveness of the drug. The lipid profile data also did not demonstrate significant differences between the two age groups; however, the comparison between younger vs. older patients' populations regarding the total cholesterol/HDL ratio and LDL/HDL ratio shows a statistically significant difference: total cholesterol/HDL 3.4 (2.12-3.66) vs. 3.64 (3.36-4.13) p = 0.0004, LDL/HDL 1.9 (0.98-2.25) vs. 2.41 (2.04-2.73) p = 0.0002. There are no differences regarding the atherogenic index (LDL-C/HDL-C) and coronary risk index (TC/HDL-C) compared to baseline., Conclusions: After six months of treatment with FIL, the older population group showed a higher level of LDL and a lower level of HDL compared to younger patients. The atherogenic index and coronary risk index are higher in patients aged ≥ 65 years, but interestingly, there were no differences when comparing the 6-month data to baseline values. This condition highlights the impact of typical risk factors that act independently of treatment with Filgotinib.

Published
2024
Full Text
View/download PDF

13. Do Ultrasound Lung Abnormalities Correlate to Biomarkers and Male Gender in Rheumatoid Arthritis Patients? A Monocentric Cross-Sectional Study.

Author

Bandinelli F, Benucci M, Mallia I, Mauro I, Pecani N, Li Gobbi F, Manfredi M, Guiducci S, Lari B, Grossi V, Infantino M, and Giannasi G

Abstract

Background : Lung ultrasound (LUS) is a tool of growing interest in Rheumatoid Arthritis (RA) oligo- symptomatic ILD to avoid. Objective : We aimed to evaluate (i) the prevalence of pleural (PLUS) and parenchymal (PAUS) abnormalities in LUS in the RA population and their possible correlation to biomarkers; (ii) the predictivity of gender, smoking habits, previous infections (past COVID-19 tuberculosis), and treatments; (iii) the differences in LUS between sexes. Methods : We collected the data of 155 (15 early and 140 late) RA patients with mild respiratory symptoms, evaluating PLUS and PAUS, in fourteen lung areas and also summing the scores (LUS-T). Results : Only 13/155 (8.4%) were completely negative; LUS correlated to age (all parameters p 0.0001), rheumatoid factor IgM (PLUS p 0.0006, PAUS p 0.02, LUS-T p 0.001) and ACPA ( p 0.001, 0.006, 0.001, respectively), and PLUS also correlated to IL6 ( p 0.02). The male gender was predictive of all LUS evaluations ( p 0.001, 0.05, 0.001, respectively), which were higher than in women ( p 0.001, 0.01, 0.001, respectively). Other potential risk factors were independent, except biological treatments, which showed a low predictivity to PLUS ( p < 0.05). Conclusions: We can conclude that LUS is a useful technique in RA low respiratory symptoms and correlates with age, the most important RA biomarkers, and male sex.

Published
2024
Full Text
View/download PDF

14. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA- i Study).

Author

Benucci M, Li Gobbi F, Damiani A, Russo E, Guiducci S, Manfredi M, Lari B, Grossi V, and Infantino M

Abstract

Background: Real-world evidence of the efficacy and adverse events of JAK inhibitor treatment (Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib) in rheumatoid arthritis is still limited. Methods: We studied 115 patients from the Rheumatology Unit of S. Giovanni di Dio Hospital affected by D2T-RA, according to the 2010 EULAR criteria. Out of the 115 patients, 17 had been treated with Baricitinib 8 mg/daily, 32 with Filgotinib 200 mg/daily, 21 with Tofacitinib 10 mg/daily, and 45 with Upadacitinib 15 mg/daily. We evaluated the clinical response after 3, 6, and 12 months of treatment and the follow-up from September 2022 to September 2023. All patients were evaluated according to the number of tender joints (NTJs), number of swollen joints (NSJs), visual analog scale (VAS), global assessment (GA), health assessment questionnaire (HAQ), Disease Activity Score (DAS28), and CDAI. Furthermore, laboratory parameters of efficacy and tolerability were evaluated. Results: All treatments demonstrated a statistically significant decrease in the DAS28 and CDAI scores, tender and swollen joint counts, VAS, HAQ, and patient global assessment (PGA) after 3, 6, and 12 months of treatment. All treatments showed similar behavior, and statistically significant decreases in circulating calprotectin, TNFα, and IL-6 were observed for all drugs after 12 months of treatment. In addition, soluble urokinase plasminogen activator receptor (suPAR) values showed significant differences at baseline and after 12 months of treatment for Filgotinib: 4.87 ± 4.53 vs. 3.61 ± 0.9 (0.009) and Upadacitinib: 6.64 ± 7.12 vs. 4.06 ± 3.61 (0.0003), while no statistically significant differences were found for Baricitinib: 3.4 ± 0.1 vs. 3.78 ± 0.1 and Tofacitinib: 3.95 ± 1.77 vs. 2.58 ± 0.1. The TC/HDL-C ratio (atherogenic index) showed significant differences when comparing Baricitinib vs. Filgotinib (0.0012), Filgotinib vs. Tofacitinib (0.0095), and Filgotinib vs. Upadacitinib (0.0001); furthermore, the LDL-C/HDL-C ratio in the Filgotinib group did not change (2.37 ± 0.45 vs. 2.35 ± 2.13 (NS)) after 12 months of treatment. Venous Thrombotic Events (VTEs) and major adverse cardiovascular events (MACEs) accounted for 1% of adverse events after treatment with Baricitinib. Herpes zoster reactivation accounted for 1% of adverse events after treatment with Filgotinib and Tofacitinib, while non-melanoma skin cancer (NMSC) accounted for 1% of adverse events after Upadacitinib treatment. Conclusions: Our real-world data from patients with RA show differences in some laboratory parameters and in the impact of lipid metabolism in JAK inhibitor treatment.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results